Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Showing results for

Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).

brain

Similar stories

Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment

An Oxford University spinout rooted in Nuffield Department of Medicine and Radcliffe Department of Medicine research was recently acquired by global biotechnology company Amgen in a deal worth up to $840 million. The acquisition highlights how the strength of Oxford’s collaborative, translational research environment, rooted in world leading science, is accelerating the development of potential new targeted treatments for cancers.

Professor Trey Ideker appointed Director of the Big Data Institute

International Women’s Day: Women Advancing Science and Global Health

Oxford joins new West Africa consortium to accelerate climate and health solutions

New Oxford-led trial explores if the immune system can be trained to control HIV

Professor Sir Nicholas White OBE KCMG FRS